Research Article
Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy
Table 2
Univariate and multivariate analyses of association between clinical parameters and overall survival.
| | Clinical features | Patient numbers | Univariate | Multivariate | HR†
(95% CI‡) | P-value | HR†
(95% CI‡) | P-value |
| | Stage (I vs II vs III) | 13 : 27 : 65 | - | 0.001∗ | 1.907
(1.147-3.171) | 0.013∗ |
| | Tumor site (Upper vs Middle vs Lower) | 28 : 48 : 29 | - | 0.905 | - | - |
| | Gender (Male vs Female) | 98 : 7 | 0.737
(0.248-2.009) | 0.513 | - | - |
| | Age (≥ vs <60 years old) | 40 : 65 | 0.726
(0.399-1.260) | 0.241 | - | - |
| | Surgery (Yes vs No) | 38 : 67 | 2.046
(1.154-3.334) | 0.013∗ | 0.353
(0.182-0.687) | 0.002∗ |
| | Radiotherapy (4000~5000cGy vs >5000cGy) | 40 : 65 | 0.7847
(0.462-1.344) | 0.381 | - | - |
| | Days from diagnosis to initial treatment (< v.s ≥29) | 57 : 48 | 0.989
(0.583-1.677) | 0.966 | - | - |
| | Days from diagnosis to complete treatment (< v.s ≥69) | 54 : 51 | 0.704
(0.405-1.185) | 0.180 | - | - |
| | Hematologic Markers |
| | Platelet count of pre-treatment (≥ vs <300,000/μL) | 34 : 71 | 0.535
(0.277-0.887) | 0.018∗ | 1.543
(0.778-3.061) | 0.217 |
| | Platelet count of post-treatment (≥ vs <300,000/μL) | 9 : 96 | 0.389
(0.078-0.704) | 0.010∗ | 2.656
(1.047-6.735) | 0.041∗ |
| | (≥ vs <9.8fl) | 51 : 50& | 1.286
(0.750-2.207) | 0.361 | - | - |
| | Hemoglobin (≥ vs <14g/dL) | 17 : 88 | 1.426
(0.745-2.583) | 0.302 | - | - |
| | White blood count (≥ vs <10,000/μL) | 12 : 93 | 0.715
(0.255-1.795) | 0.432 | - | - |
| | Absolute Neutrophil count (≥ vs <4483/μL) | 53 : 52 | 0.617
(0.362-1.041) | 0.070 | - | - |
| | Neutrophil percentage (≥ vs <73.4%) | 53 : 52 | 0.729
(0.431-1.232) | 0.238 | - | - |
| | Absolute Monocyte count (≥ vs <449/μL) | 53 : 52 | 0.756
(0.444-1.276) | 0.292 | - | - |
| | Monocyte percentage (≥ vs <7%) | 53 : 52 | 0.955
(0.564-1.615) | 0.861 | - | - |
| | Absolute lymphocyte counts (≥ vs <1042/μL) | 53 : 52 | 1.627
(0.969-2.823) | 0.065 | - | - |
| | Lymphocyte percentage (≥ vs <16%) | 53 : 52 | 1.997
(1.205-3.548) | 0.008∗ | 0.431
(0.131-1.419) | 0.168 |
| | Biomarker of Inflammation |
| | Platelet to- ratio (≥ vs <236) | 53 : 52 | 0.632
(0.368-1.064) | 0.083 | - | - |
| | Platelet-to-Lymphocyte(%) ratio (≥ vs <14605) | 53 : 52 | 0.514
(0.316-0.911) | 0.021∗ | 0.542
(0.245-1.200) | 0.133 |
| | Neutrophil-to-Lymphocyte ratio (≥ vs <4.35) | 53 : 52 | 0.507
(0.290-0.847) | 0.010∗ | 0.804
(0.258-2.504) | 0.709 |
|
|
, hazard ratio; ‡CI, confidence interval; , mean platelet volume; , absolute lymphocyte count; &no data of 4 patients. |
